Annovis Bio (NYSE: ANVS) announced the promotion of Cheng Fang, Ph.D., to chief scientific officer, effective immediately. Fang, who joined the company in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across Annovis’ Alzheimer’s disease and Parkinson’s disease programs, including translational science, clinical development, biomarker strategy and regulatory interactions.
The promotion comes as Annovis advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer’s disease study and a subsequent New Drug Application submission. Fang has played a key role in advancing the company’s clinical development efforts and will lead its scientific strategy through upcoming clinical and regulatory milestones, according to the company.
Annovis Bio is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients.
For more information, visit the company’s website at www.annovisbio.com and follow on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS.
